Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent BioBlast® Updates

Update on MSD Challenges to Johns Hopkins’ Pembrolizumab MOT Patents

Oct 3, 2024

On 3 October 2024, the US Patent Trial and Appeal Board (PTAB) instituted inter partes review (IPR) of Johns Hopkins University’s US patent no. 11,643,462 in IPR2024-00648.  MSD filed a petition on 13 March 2024, challenging the validity of the patent, which is...

NHS Launches Consultation on Phased Rollout of Obesity Drug Tirzepatide

Oct 3, 2024

The UK National Health Service (NHS) launched a consultation on a phased rollout of Eli Lilly’s obesity drug Mounjaro® (tirzepatide), prioritising patients who are most likely to benefit from weight loss.  In a proposal made to National Institute for Health and Care...

Eisai Submits Application for Leqembi® in Saudi Arabia

Oct 2, 2024

On 2 October 2024, Eisai reported that it has submitted an application for approval of Leqembi® (lecanemab) in Saudi Arabia for Alzheimer’s disease . The news follows approval of Leqembi® in the UK for the treatment of mild cognitive impairment (MCI) and mild dementia...

Study Comparing Denosumab with Romosozumab Published in Nature

Oct 1, 2024

On 1 October 2024, the prestigious journal Nature published an article describing a retrospective cohort study comparing the efficacy of Evenity® (romosozumab) and Prolia® (denosumab) in treating male osteoporosis over 12 months, focusing on bone mineral density (BMD)...

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here